Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
VANCOUVER, British Columbia and REHOVOT, Israel - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), known for its patented Botanical Synthesis technology, has announced that its flagship product VINIA® has surpassed $50 million in cumulative sales. The majority of these sales have been recorded since the product’s launch in the U.S. market less than four years ago. According to InvestingPro data, the company’s revenue grew by an impressive 112% in the last twelve months, with analysts setting price targets between $12 and $18 per share.
VINIA®, a dietary supplement derived from red grape cells, utilizes the company’s unique Botanical Synthesis platform. Since its U.S. debut in May 2021, VINIA® has garnered a substantial customer base, with over 50,000 active U.S. subscribers to its recurring delivery packages as of February 16, 2025. The product’s success is supported by clinical trials validating its heart-health benefits, such as improved blood flow and arterial dilation. The company maintains strong gross profit margins of 54%, indicating efficient production processes.
The company’s CEO, Ilan Sobel, expressed confidence in BioHarvest’s technology and its ability to produce plant-based molecules at scale. He highlighted the role of VINIA® as a testament to the efficacy of their Botanical Synthesis process, which has taken 15 years and more than $100 million to develop. Sobel also noted the expansion of their Contract Development and Manufacturing Organization (CDMO) Services division, which is currently developing multiple compounds for partners in the pharmaceutical and nutrition industries.
In anticipation of continued growth, BioHarvest is planning a significant increase in its production capabilities. A new facility capable of producing 100 tons per year is expected to become operational by late 2026, quadrupling the company’s current output. InvestingPro analysis reveals several key factors affecting the company’s expansion plans, with 8 additional exclusive insights available to subscribers.
BioHarvest Sciences Inc. specializes in growing plant-based molecules without cultivating the plants themselves, an approach that offers environmental benefits. The company operates two major business verticals: providing CDMO services and creating proprietary nutraceutical health and wellness products. With a beta of 1.51, the stock shows higher volatility than the market, while analysts anticipate continued sales growth in the current year.
The information in this article is based on a press release statement from BioHarvest Sciences Inc. The company encourages customers to leave honest feedback on their products, offering a 30-day supply of VINIA® for reviews, regardless of their sentiment. VINIA® has received over 8,000 customer reviews with a verified average rating of 4.8 out of 5.
In other recent news, BioHarvest Sciences Inc. has reported a significant corporate update, having filed a material change report with the United States Securities and Exchange Commission. This filing typically covers major events that could influence the value of the company’s securities, including changes in operations, financial condition, or corporate structure. The specific nature of the change was not detailed in the summary provided, but it’s a key development that investors should note.
In addition to this, BioHarvest Sciences has seen substantial growth, having doubled its core VINIA® capsule business in 2024. The company also launched its CDMO Services division and partnered with ingredient solutions leader, Tate & Lyle. Furthermore, BioHarvest expanded its Direct-to-Consumer products division, ending 2024 with approximately 50,000 active subscribers in the USA and an exit run rate nearing US$30 million.
With strategic investments in an 80,000 square foot corporate campus in Yavneh, Israel, and the digitization of production processes, BioHarvest improved gross margin profiles from 44% in Q3 2023 to 56% in Q3 2024, with expectations to exceed 60% in 2025. The company also achieved a significant capital markets milestone with its listing on the Nasdaq, aiming for adjusted EBITDA profitability in the second half of 2025. These are the latest developments for BioHarvest Sciences, a company that continues to focus on operational execution to support commercialization at scale.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.